皮下与静脉托珠单抗治疗巨细胞动脉炎相关主动脉炎的对比:196例多中心研究
这项多中心观察性研究纳入196例经影像学诊断的巨细胞动脉炎(GCA)相关主动脉炎患者,比较皮下(SC)与静脉(IV)托珠单抗(TCZ)的疗效。24个月随访时,SC组达到EULAR定义缓解的比例显著更高(83.3% vs 80.6%;P < 0.05),但影像学缓解和无全身炎症两组相当,激素节约效应相似。
要点
- SC TCZ在24个月EULAR缓解率上略优于IV TCZ(83.3% vs 80.6%;P < 0.05)。
- 影像学缓解和无全身炎症两组无显著差异。
- 两组激素节约效应相似,基线特征可比。
核心结论
- 在GCA相关主动脉炎真实世界队列中,SC TCZ在达到EULAR定义缓解上略优于IV TCZ,但影像学缓解无显著差异。
研究设计与样本
- 多中心观察性研究纳入196例经影像学诊断的GCA相关主动脉炎并接受TCZ治疗的患者,按给药途径分为IV组(110例)和SC组(86例)。
主要发现
- 196例患者中148例女性,平均年龄69.8 ± SD 9.4岁,两组基线临床特征和炎症标志物可比。
- 24个月随访时EULAR定义缓解率SC组显著高于IV组(83.3% vs 80.6%;P < 0.05)。
- 影像学缓解率和无全身炎症率两组相当,激素节约效应相似。
关键数值与推荐
- GCA诊断依据1990年美国风湿病学会标准、颞动脉活检和/或血管影像。
- 主动脉炎通过18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描识别。
- 主要结局包括EULAR缓解、临床和影像学缓解、无全身炎症及激素节约效应。
临床怎么用
- 对于GCA相关主动脉炎患者,SC TCZ可作为与IV TCZ相当的给药选择,尤其在追求EULAR缓解时可能略有优势。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aortitis associated with giant cell arteritis (GCA) is a severe manifestation, potentially leading to aneurysms and aortic dissection. Tocilizumab (TCZ) has demonstrated efficacy in the treatment of GCA, both intravenously or subcutaneously administered. However, pivotal studies did not specifically evaluate aortic involvement, and no comparison of intravenous (IV) versus subcutaneous (SC) TCZ has been performed in patients with GCA-related aortitis. The objective of this study was to compare the effectiveness of TCZ according to the administration route in patients with GCA-associated aortitis under clinical practice conditions. METHODS: This was a multicenter observational study including 196 patients diagnosed with GCA-associated aortitis by imaging and treated with TCZ. Patients were grouped by administration route: IV or SC. GCA was diagnosed following the 1990 American College of Rheumatology criteria, temporal artery biopsy, and/or vascular imaging. Aortitis was identified using 18F-fluorodeoxyglucose positron emission tomography/computed tomography scan. Main outcomes included EULAR remission, clinical and imaging remission, absence of systemic inflammation, and glucocorticoid-sparing effect. RESULTS: Of 196 patients (148 women; mean age 69.8 ± SD 9.4 years), 110 received IV TCZ and 86 SC TCZ. Baseline clinical characteristics and markers of inflammation were comparable between groups. The glucocorticoid-sparing effect was similar. At 24-month follow-up, EULAR-defined remission was significantly more frequent in the SC group (83.3% vs 80.6%; P < 0.05). However, rates of imaging remission and absence of systemic inflammation were comparable between treatment arms. CONCLUSIONS: In this real-world cohort of GCA-associated aortitis, SC TCZ showed slightly greater effectiveness than IV TCZ in achieving EULAR-defined remission, whereas no significant differences were observed between both routes regarding imaging remission.
引用
- Secada-Gómez C, Loricera J, Martín-Gutiérrez A, et al. Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients. Arthritis Care Res (Hoboken). 2026. PMID: 41531143. doi:10.1002/acr.80006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。